Cardiokinetix

Cardiokinetix – Changing the Shape of Heart Failure® The Company, based in Menlo Park, CA, has developed a novel transcatheter implant called the Parachute® Ventricular Partitioning Device (Parachute). The Parachute intends to treat heart failure resulting from a heart attack in patients worldwide by improving overall cardiac function. Patient Unmet Needs Heart failure (HF) imposes one of the highest disease burdens of any medical condition in the world with an estimated 23 million patients experiencing HF. Heart failure is also one of the most resource-intensive conditions with direct and indirect costs in the United States estimated at $39.2 billion in 2010. The overall mortality and readmission rates for heart failure continue to remain unacceptably high even with the array of available drugs, devices, and/or surgical techniques.